흉선암 / 흉선종: 국가별 치료 선택지

임상시험 진행 중

• Surgery; postoperative radiation therapy; induction chemotherapy; chemoradiation; platinum-based chemotherapy regimens; biological therapies including octreotide/prednisone, sunitinib, everolimus, lenvatinib; pembrolizumab under clinical evaluation; clinical trials임상시험임상시험InvestigationalUnited States · No biomarker required by fetched NCI PDQ framework; Early-stage, locally advanced, inoperable, metastatic, and recurrent thymoma/thymic carcinoma contexts. · NCI PDQ is an evidence summary, not a payer/regulator source. Many systemic options are based on small studies in rare tumors and are not automatically approved or available for thymic epithelial tumors. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific approvals need separate verification. National Cancer Institute (NCI) — national cancer agency evidence summary
• Pembrolizumab (MK-3475) plus lenvatinib, carboplatin, and paclitaxel; KFA115 alone or with pembrolizumab임상시험 · NCT05832827임상시험Trial only (registry)Japan · No thymic carcinoma biomarker requirement stated in fetched registry records; First-line for previously untreated advanced or recurrent thymic carcinoma in NCT05832827; selected advanced cancers including thymic carcinoma in NCT05544929. · Registry records do not establish PMDA approval, reimbursement, routine availability, active enrollment beyond the stated status, or individual eligibility. NCT05544929 is a broad cohort rather than thymic carcinoma-only. Confidence/conflicts: High for Japan registry-listed trial activity; local approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
• Sunitinib; palbociclib; paclitaxel plus cisplatin; neoadjuvant docetaxel/cisplatin; KFA115 with pembrolizumab; anetumab ravtansine with cisplatin/gemcitabine broad solid-tumor context임상시험 · NCT02623127임상시험Trial only (registry)Korea · No biomarker requirement stated in fetched Korea registry records; Metastatic or recurrent thymic carcinoma; recurrent or refractory advanced thymic epithelial tumor; locally advanced stage III or IV thymic cancer; broad selected advanced cancers including thymic carcinoma. · Several Korea records are completed, terminated, or unknown status and do not imply current access. The broad-cohort studies do not prove thymic carcinoma-specific enrollment at every listed site. Registry records do not establish MFDS approval, reimbursement, or standard-of-care use. Confidence/conflicts: Medium-high for Korea registry-listed trial activity; current treatment access and regulator status remain unverified. ClinicalTrials.gov — clinical-trial registry
• CD70-targeted CAR-T cells; target-selected CAR-NK cells with lymphodepletion; pembrolizumab plus chemotherapy; sacituzumab tirumotecan; tislelizumab plus anlotinib; postoperative proton radiotherapy plus platinum-based chemotherapy context; adjuvant radiotherapy; neoadjuvant CAP or nab-paclitaxel/carboplatin임상시험 · NCT07181720임상시험Trial only (registry)China · CD70-positive status for the CD70 CAR-T advanced solid tumor study; CD30, CD5, or mesothelin target selection for the CAR-NK study; no biomarker stated for other fetched China records; CD70-positive advanced solid tumor including thymic carcinoma; relapsed/refractory B2 thymoma or thymic carcinoma; locally advanced or metastatic thymic carcinoma; second-line thymoma/thymic carcinoma; postoperative thymus tumor radiotherapy; stage II/III thymoma after complete resection; potentially resectable locally advanced thymic epithelial tumors. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment for every study, or individual eligibility. Some studies are not yet recruiting or have unknown status, and broad solid-tumor studies require biomarker or protocol-specific confirmation. Confidence/conflicts: High for China registry-listed thymic epithelial tumor trial activity; NMPA approval/routine access not established. ClinicalTrials.gov — clinical-trial registry